EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward

Beta Sigma Quant 11 Followers Follow Summary EyePoint is rated a speculative strong buy, with a revised fair value of $19 per share, despite increased regulatory risk after LUGANO’s primary endpoint miss. LUGANO lowered estimated wet-AMD approval probability to 30%, but its strong durability results reinforced DURAVYU’s competitive and commercial potential. LUGANO’s primary endpoint miss appears largely driven by unusually unfavorable circumstances, supporting an estimated 70–75% chance that LUCIA meets its primary endpoint. DCF valuation assumes 15% penetration among treatment-naïve wet-AMD patients and 2% annual switching, with DME contributing nearly half of EYPT’s risk-adjusted value. Current valuation offers substantial compensation for binary risk, with a 70% chance EYPT’s fair value is at least $14 per share and a 20% chance of a $51 scenario. Anastasiia Dernova/iStock via Getty Images In my previous article , I rated EyePoint ( EYPT ) a Buy based on a probability-adjusted DCF valuing DURAVYU at ~$2.9B pre-dilution, while highlighting an approximately 39% risk of Phase 3 failure, i.e., failure to meet its primary endpoint. That risk This article was written by Beta Sigma Quant 11 Followers Follow I am an individual investor with an engineering and economics background, focusing on analytical and quantitative approaches to company valuation. I conduct this work independently as a personal investment activity, alongside my primary professional occupation in a different sector. In my professional career, I initially conducted cost-benefit as well as economic and social analyses of major infrastructure projects. I am now more focused on reviewing and assessing the quality of studies produced by others. In parallel, over time, I have developed a particular interest in biotechnology and healthcare, especially early-stage and preclinical assets where uncertainty is high. I assessed the work of different analysts and realized that, although underlying assumptions and drivers are sector-specific, the tools and methodologies are in fact quite similar to those I used to assess the financial viability of major infrastructure projects.More specifically, I tend to focus on mid-cap biotechnology and pharmaceutical companies (such as DBV Technologies or EyePoint Pharmaceuticals) ahead of key binary events, typically late-stage clinical readouts (e.g., Phase 3). My approach consists of forming an initial view on the probability of success, potential market opportunity, and key risks such as dilution or financing needs. When I identify a potential gap between my assessment of fair value and the prevailing market valuation, I then conduct a more in-depth analysis. Building on my background and professional experience, I use probabilistic frameworks and modeling tools to assess clinical success probabilities and potential market outcomes, including scenario-based and probabilistic DCF approaches.As I invest my own capital in the situations I analyze, I place strong emphasis on rigor and consistency in my approach. Writing and publishing my analysis is an integral part of this process: it forces me to structure assumptions clearly, refine my initial views, challenge my own reasoning, and double-check and justify all hypotheses. Publishing on Seeking Alpha also provides the opportunity to confront my views with external perspectives and to engage with a community of investors on complex and often uncertain investment cases. My objective is to identify situations where risk and reward may be mispriced. In addition, investing in biotechnology and healthcare supports the development of products and devices that have the potential to improve patient lives, which is another aspect that I value highly. Analyst’s Disclosure: I/we have a beneficial long position in the shares of EYPT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.